Physician profile
Bernard J Lichtenstein
NPI 1104878073
$2,442.21
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $285 · 2021: $389 · 2022: $199 · 2023: $125 · 2024: $47.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $854.30 | 2019-2022 | |
| Novo Nordisk INC | $391.25 | 2019-2023 | Wegovy |
| Abbvie INC. | $260.05 | 2019-2021 | |
| Amgen INC. | $251.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $204.76 | 2019-2024 | Farxiga |
| Allergan, INC. | $138.04 | 2019-2020 | |
| Melinta Therapeutics, LLC | $119.37 | 2019 | |
| Vision Quest Industries INC. | $59.59 | 2022-2024 | Oactive Align Custom R |
| Glaxosmithkline, LLC. | $44.24 | 2020-2021 | |
| Genentech USA, INC. | $19.66 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.97 | 2020 | |
| Shire North American Group INC | $17.37 | 2019 | |
| Lilly USA, LLC | $14.09 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Lichtenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.